24 results about "High cholesterol" patented technology

The invention belongs to the technical field of microorganisms and biological medicines, and particularly relates to marine-source lactobacillus plantarum HYC-1 with cholesterol lowering and alpha-glucosidase inhibiting activity and application of the marine-source lactobacillus plantarum HYC-1. The novel lactobacillus plantarum HYC-1 is screened from intestinal tracts and contents of marine fishes, the strain has efficient cholesterol lowering activity and alpha-glucosidase inhibition activity at the same time, and experimental results show that the in-vitro cholesterol lowering rate of lactobacillus plantarum HYC-1 fermentation liquor can reach 89.4%, the alpha-glucosidase inhibition rate can reach 93.5%, and the lactobacillus plantarum HYC-1 fermentation liquor can be used for preparing the cholesterol lowering agent. One bacterium has double effects and unique functions; besides, the strain shows excellent tolerance and high safety, so that the strain can be widely applied to food, health care products and medicines, especially to preparation and research and development of medicines with the efficacy of regulating blood fat and blood sugar.

The invention discloses a mechanical response type engineered mesenchymal stem cell exosome preparation for treating diseases caused by fibrosis inflammation, a preparation method and application, and the exosome preparation is an exosome which is secreted by mesenchymal stem cells and has high cholesterol and high-efficacy protein. The exosome is prepared by culturing mesenchymal stem cells on a hydrogel matrix in a modulus hardness range of 1-50KPa, the exosome secretion amount of a single cell is (3-5) * 10 < 4 > / cell, the cholesterol content is (1-10) nM / 5mg exosome, and the size of the exosome is 110-140nm; the high-efficacy protein is a key functional protein for regulating and controlling the biological activity of the exosome and the cell action efficiency. The cholesterol content in the exosome is precisely regulated and controlled, the cytoplasm delivery efficiency and tissue penetrability of the exosome are improved, a whole-process control system of hydrogel preparation, stem cell culture and exosome purification is constructed, and the stability of the preparation and the yield of the exosome are improved.

The utility model relates to the technical field of cholesterol extraction, and discloses a reaction device for extracting cholesterol from alcohol residues, which comprises a reaction kettle and a crushing and screening mechanism arranged at the upper end of the reaction kettle, the crushing and screening mechanism comprises a crushing pipe, two groups of crushing tooth rollers are rotationally arranged in the crushing pipe, and one end of one group of crushing tooth rollers penetrates through the crushing pipe and is driven by a second motor; through the design of a crushing tooth roller, a sieve plate and a turntable of the crushing and screening mechanism, the crushing tooth roller can crush alcohol residues, screen the crushed alcohol residues and remove large-particle impurities in the alcohol residues, so that the alcohol residues with uniform texture are obtained, material transfer in an intermediate link is avoided, time and labor are saved, and the production efficiency is improved. The alcohol residues can be uniformly mixed with the solvent, so that the pollution risk in the transfer process is reduced while the production efficiency is improved, and the product quality after cholesterol extraction is improved.

The present application provides a blood sugar regulating health care composition, which utilizes the combination of effective components in the fruit pulp and seeds of Momordica balsamifera, and the effective components of Chinese herbal medicines, to help the blood sugar of type 2 diabetes patients to decrease steadily. The compound food composition contains 20-60wt% Momordica balsamifera component, 5-20wt% Momordica balsamifera seed component, 1-20wt% cinnamon component, 1-15wt% monk fruit component, and 1-10wt% licorice component. In addition, the blood sugar regulating health care composition can also regulate the comprehensive indexes of patients with high blood lipids, high cholesterol, abnormal liver metabolic enzymes, and abnormal uric acid at the same time.

The present invention relates to the use of cellobiofructose (CBF) as a dietary fiber and / or prebiotic component in food products, food product additives, nutraceuticals and / or beverages or for increasing the growth of probiotic microorganisms. The invention further relates to CBF and compositions containing it for use in the prevention and / or treatment of obesity, constipation, high cholesterol, diabetes, hypertension, and / or heart disease. The invention further encompasses a method for the (recombinant) production of cellobiofructose (CBF), as described herein, using a polypeptide having levansucrase activity which comprises or consists of a polypeptide having at least 80 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 1.

The invention discloses siRNA for inhibiting ASGR1 expression and application of the siRNA, and belongs to the technical field of molecular biology. The preparation method comprises the following steps: firstly, designing siRNA according to an ASGR1 sequence, and carrying out transient transfection on the designed siRNA; according to the present invention, RT-qPCR (reverse transcription-quantitative polymerase chain reaction) and Western blotting are adopted to verify the ASGR1 expression inhibition effect; experiments prove that the siRNA molecule provided by the invention can be used for effectively inhibiting the expression of ASGR1; the protein is further delivered into a body through a carrier, the mRNA level is obviously reduced, protein expression is obviously inhibited, and a new method is provided for research and development of drugs for treating fatty liver, hyperlipidemia and high cholesterol.

The invention relates to application of a horseradish tree leaf extract in preparation of fat-reducing medicines or functional foods, and belongs to the technical field of medicines. The application comprises the following steps that S1, mice are evenly divided into five groups according to the weight of the mice after being fed for one week under the conditions of constant temperature and humidity, each group comprises eight mice, and the five groups comprise a normal control Con group, a high-fat and high-cholesterol HFC model group, a low-dose moringa oleifera leaf extract L-MOL intervention group, a high-dose moringa oleifera leaf extract H-MOL intervention group and a positive drug rosiglitazone RSG intervention group; s2, except the normal control Con group, high-fat feed is administered to other groups, administration is performed in an intragastric administration mode at ten o'clock in the morning every day, the weight of the mice is observed and recorded, and continuous administration is performed for 60 days; s3, stopping taking medicine for 24 hours after the step S2, anesthetizing and sampling blood, dissecting after cervical vertebra dislocation and killing, dissecting the abdomen of the mouse, taking a picture, and recording the subcutaneous fat weight and the white fat weight of the abdomen of each group of mouse. The moringa oleifera leaf extract provided by the invention shows an excellent fat reducing effect.

Provided herein are processes of producing volixibat and volixibat analogs, or their pharmaceutically acceptable salts, hydrates, or solvates thereof. Further provided herein are compounds of volixibat analogs, intermediates, or their pharmaceutically acceptable salts, hydrates, or solvates thereof. Additionally provided herein are crystalline forms of potassium volixibat salts. Provided herein are pharmaceutical compositions and dosage forms of the compositions comprising the compounds as described herein. Further provided herein are methods and kits of treating liver disease, hyperlipidemia, high cholesterol, arteriosclerosis, or Syndrome X using the compositions comprising the compounds as described herein.

The invention discloses kluyveromyces marxianus genetically engineered bacteria and application thereof, and belongs to the technical field of bioengineering. The invention discloses a kluyveromyces marxianus genetically engineered bacterium. The kluyveromyces marxianus genetically engineered bacterium is prepared by the following steps: firstly, screening to obtain a kluyveromyces marxianus strain with high ergosterol yield; on the basis, inducing and separating a MATa haploid strain; then, through the introduction of heterologous DHCR24 and DWF5 genes, the weakening of a competitive pathway gene ERG6, the improvement of the metabolic flux of a squalene pathway in a sterol synthesis process, the compartment engineering of a peroxisome region of a mevalonic acid pathway, the knockout of an hypoxia inhibition transcription factor ROX1, the improvement of cofactor supply, the optimization of a yeast lipid pathway and other metabolic engineering optimization reconstructions, the expression of the yeast lipid pathway is improved; and an engineering strain with high cholesterol yield is constructed and obtained. Through fed-batch fermentation, efficient and stable synthesis of cholesterol is achieved, the yield reaches 7.64 g / L, and a foundation is laid for biological manufacturing of cholesterol.

The invention relates to the technical field of polypeptide compounds, in particular to a preparation method of a cholesterol-modified brain-targeted peptide Angiopep-2, which comprises the following steps: (a) sequentially coupling amino acids protected by Fmoc to resin from the C terminal to the N terminal according to the peptide sequence of the brain-targeted peptide Angiopep-2 by adopting a solid-phase synthesis method, and removing Fmoc protecting groups to obtain peptide resin; (b) carrying out a first condensation reaction on the peptide resin and succinic anhydride, then carrying out a second condensation reaction with cholesterol, and carrying out cutting treatment; when the first Thr in the peptide sequence is coupled, the amino acid protected by the Fmoc is at least one of Fmoc-N (Dmb)-Thr (tBu)-OH and Fmoc-N (Hmb)-Thr (tBu)-OH. According to the preparation method disclosed by the invention, the raw material cost can be remarkably reduced, and meanwhile, the yield and the purity of the brain-targeted peptide Angiopep-2 modified by cholesterol are improved.

This invention belongs to the field of biomedical technology and discloses a soybean-modified peptide for the prevention and treatment of cardiovascular diseases. Addressing the problem that the original peptide VAWWMY is easily degraded by enzymes in the gastrointestinal tract and has difficulty achieving a significant lipid-lowering effect in vivo, this invention modifies the amino acid sequence of the original peptide to SAIWMY. The modified peptide SAIWMY has higher cholesterol-lowering activity than the original peptide, is less susceptible to degradation by gastrointestinal enzymes and is more stable, has higher safety than cholestyramine, and is more effective than cholestyramine in lowering cholesterol and triglycerides in the liver, exhibiting better lipid-lowering potential. It can be used to prepare drugs for the prevention or treatment of cardiovascular diseases (such as hyperlipidemia, atherosclerosis, and coronary heart disease), fatty liver disease, and diabetes, and can also be used to prevent or treat obesity.

The application discloses the use of ACY-1 modulators as a therapeutic target for fatty liver disease and drug screening. By constructing a HepG2 cell lipid deposition model, it is found for the first time that ACY1 overexpression can exacerbate cell triglyceride accumulation; by constructing a MASH mouse model induced by a high-fat high-cholesterol high-fructose diet, it is found that ACY1 overexpression can exacerbate MASH progression; based on these findings, a drug screening method for preventing or treating fatty liver disease is constructed, and 2-hydroxyhexanoic acid (2-HHA) is screened out, which can significantly inhibit the in vitro enzyme activity of ACY1, and can alleviate abnormal cell triglyceride accumulation caused by palmitic acid-oleic acid stimulation at the cell and animal levels, and significantly improve the weight gain, liver lipid deposition, fatty degeneration, inflammatory infiltration and fibrosis of MASH mice induced by a high-fat high-cholesterol high-fructose diet, and the like, in addition, the inhibitor 2-hydroxyhexanoic acid can significantly reduce the abnormally increased serum ALT, AST and liver TC and TG of MASH mice.

The invention discloses a compound and application thereof in preparation of a blood fat reducing medicine. Compounds 1-5 are separated from synsepalum dulcificum kernels through multiple separation means. The blood fat reducing activity of the compounds 1-5 is systematically evaluated through a zebra fish model. Experimental results show that the compounds 1-5 have remarkable blood fat reducing activity on a zebra fish high-cholesterol model induced by high-fat feeding within a certain concentration range, have concentration dependence and have good potential in preparation of the blood fat reducing medicine.

The present invention relates to a recombinant yeast strain having sterol productivity, a preparation method therefor and a use thereof, and more specifically, to a recombinant yeast strain capable of producing cholesterol and cholesterol precursors in a high yield through the deletion of ERG5 and ERG6 genes and the introduction of DHCR24 and DHCR7 genes by codon-optimizing same in multiple or with a codon context method; and a production method therefor and a use thereof. In addition, disclosed are: a method for producing a recombinant yeast strain with increased production yields of cholesterol and cholesterol precursors by the additional introduction of gene tHMG1, ERG2, ERG3, ERG27, or UPC2-1 in the prepared recombinant yeast strain; and a use thereof.

The present invention provides an application of a pharmaceutical composition in preparation of a cholesterol lowering drug, and particularly provides a product composition, which comprises: (i) a first pharmaceutical composition, which contains (a) a first active component, which is diol-type ginsenoside and a pharmaceutically acceptable carrier; and (ii) a second pharmaceutical composition, the second pharmaceutical composition containing (b) a second active ingredient, the second active ingredient being a statin drug, and a pharmaceutically acceptable carrier; wherein the first pharmaceutical composition and the second pharmaceutical composition are different pharmaceutical compositions or the same pharmaceutical composition. The product composition disclosed by the invention can be used for synergistically preventing and / or treating high cholesterol related diseases.

The present application relates to the technical field of animal model construction, and relates to a fetal origin atherosclerosis susceptible model and a construction method and application thereof.The construction method of the fetal origin atherosclerosis susceptible model comprises the following steps: S1, selecting healthy pregnant ApoE- / - mice, subcutaneously injecting dexamethasone twice a day at 16-17 days of pregnancy, the injection amount of dexamethasone is 0.6-0.8 mg / kg of the body weight of the pregnant female mouse, and the pregnant female mouse is free to eat; S2, the pregnant female mouse naturally gives birth to F1 generation, the male and female offspring are weaned and separated into cages at 3-4 weeks after birth, and continue to be normally fed until 6-7 weeks after birth, and then high-fat high-cholesterol feed is given to feed until 18-19 weeks; the fetal origin atherosclerosis susceptible model is obtained.The present application successfully constructs the fetal origin atherosclerosis susceptible model by injecting dexamethasone at a specific time, and the atherosclerosis lesion of the model presents a significant aggravation effect.

The invention discloses a traditional Chinese medicine composition for treating a high cholesterol phlegm-damp and turbid obstruction syndrome. Comprising the following raw material medicines in parts by weight: 10-15 parts of radix bupleuri, 15-22 parts of bighead atractylodes rhizome, 15-22 parts of glossy privet fruit, 12-17 parts of semen cassiae, 11-15 parts of rhizoma alismatis, 21-30 parts of gynostemma pentaphylla, 14-20 parts of turmeric, 18-25 parts of salvia miltiorrhiza, 7-10 parts of safflower, 12-18 parts of poria cocos, 8-12 parts of oriental wormwood, 21-30 parts of hawthorn, 14-20 parts of sedum sarmentosum, 10-15 parts of red yeast rice, 12-18 parts of white paeony root, 6-10 parts of fructus amomi, 7-10 parts of schisandra chinensis and 6-8 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention is researched and developed on the basis of diagnosis and treatment of complex pathogenesis of the high-cholesterol phlegm-damp and turbid obstruction syndrome in traditional Chinese medicine, and has an expected effect on treatment of the high-cholesterol phlegm-damp and turbid obstruction syndrome.

The invention provides a method for biologically modifying kelp fucoidan by utilizing monascus fermentation, a product and application thereof. The method comprises the step of fermenting kelp by utilizing monascus. According to the method, monascus fermentation is adopted, so that the total sugar content of fucoidan can be remarkably increased, and the content of sulfate groups and uronic acid is reduced to a certain extent; compared with an unfermented kelp product, the cholesterol binding rate, the cholate adsorption capacity and the pancreatic lipase inhibition rate of the kelp fucoidan prepared by the method disclosed by the invention are improved, so that the kelp fucoidan prepared by the method disclosed by the invention has better blood fat reducing activity; in addition, compared with some existing hypolipidemic products, the kelp fucoidan prepared by the invention has higher cholesterol binding capacity.

The invention relates to the technical field of animal model construction, in particular to a fetal-derived atherosclerosis susceptibility model and a construction method and application thereof. The construction method of the fetal-derived atherosclerosis susceptibility model comprises the following steps that S1, a healthy fertilized ApoE- / -mouse is selected, dexamethasone subcutaneous injection is conducted twice a day after 16-17 days of pregnancy, the injection amount of dexamethasone every time is 0.6-0.8 mg / kg of the weight of a fertilized female mouse, and the fertilized female mouse freely diets; s2, the fertilized female rats produce naturally to obtain an F1 generation, weaning is conducted 3-4 weeks after birth, male and female newborn rats are separated into cages, normal diet feeding continues to be conducted till 6-7 weeks after birth, and then the newborn rats are fed with high-fat and high-cholesterol feed for 18-19 weeks; the fetal-derived atherosclerosis susceptibility model is obtained. The dexamethasone is injected for a specific time, a fetal-derived atherosclerosis susceptible model is successfully constructed, and atherosclerosis lesion of the model shows a remarkable aggravating effect.

The invention discloses a method for preparing low-fat mayonnaise based on proteoglycan-based microgel, and belongs to the technical field of food processing. The method comprises the following steps: preparing a soybean protein isolate and Arabic gum compound, preparing microgel particles from top to bottom, mixing the microgel particles with yolk in different proportions, adding edible white granulated sugar, edible salt, white vinegar and soybean oil, homogenizing under certain conditions to obtain the low-fat mayonnaise, and observing the appearance difference of the low-fat mayonnaise. And the rheological property of the low-fat mayonnaise is measured. Although the traditional mayonnaise is popular with consumers, the cholesterol content of the traditional mayonnaise is high, the cholesterol of a human body is easily increased, and the traditional mayonnaise is not friendly to the health of people with high cholesterol and hyperlipidemia. The low-fat mayonnaise which is low in cholesterol content and excellent in rheological property is developed by constructing the proteoglycan-based microgel, and a new path is provided for expanding the consumer market of low-fat mayonnaise food.

The invention relates to a peanut protein vegetarian sausage. The peanut protein vegetarian sausage is prepared from raw materials comprising the following ingredients in terms of parts by weight: 50 to 100 parts of low-temperature defatted peanut protein powder, 5 to 50 parts of soybean protein isolate, 5 to 50 parts of vital wheat gluten, and 0.1 to parts of modifier. The vegetarian sausage has a protein content of 60% or more, zero cholesterol and low fat, and has the characteristics of good taste, being rich in nutrients and convenience to eat. The invention further discloses a preparation method of the peanut protein vegetarian sausage. The preparation method is a pure physical processing method with a high degree of automation, and the processing is free from any pollutant discharge.

The invention discloses construction of a cholesterol self-targeting carbon dot and application of the cholesterol self-targeting carbon dot in atherosclerosis and tumors. The carbon dot is synthesized from beta-cyclodextrin, L-arginine and ammonium fluoride through a hydrothermal method. The preparation method comprises the following steps: dissolving beta-cyclodextrin, L-arginine and ammonium fluoride in a sodium hydroxide solution, carrying out ultrasonic dissolution, transferring the solution into a polytetrafluoroethylene liner, putting the liner into a stainless steel high-pressure kettle, and carrying out heating reaction in a muffle furnace; and after the reaction is finished and a reaction system is cooled to room temperature, taking out a solution, putting the solution into a dialysis bag for dialysis purification, and after dialysis is finished, freeze-drying the solution to obtain the carbon dots. The carbon dots prepared by the invention can target cholesterol, have near-red fluorescence emission, and can be used for imaging and treatment of high cholesterol diseases (atherosclerosis and tumors).

The application provides an additive and feed for producing selenium-rich low-cholesterol functional eggs and application thereof, and belongs to the technical field of animal breeding feed. The feed additive comprises ganoderma lucidum fermented mulberry leaves and selenium-rich yeast with a mass ratio of 20000-30000:0.2-0.3. The ganoderma lucidum fermented mulberry leaves are added in a mass percentage of 2-3 %, and the selenium-rich yeast is added in a selenium mass percentage of 0.2-0.3 mg / kg. The addition of the basic daily ration ensures that the selenium content in eggs is stable within the selenium-rich egg industry standard (GH / T 1135-2017) and does not exceed the standard. Compared with the eggs of chickens fed with the basic daily ration, the cholesterol content is greatly reduced and is much better than the effect of the daily ration added with unfermented mulberry leaves, thereby solving the problem of high cholesterol in ordinary eggs and meeting the market demand for functional food. Meanwhile, the produced eggs maintain the stability of the core nutritional components of eggs and take into account the functionality and nutritional value.

The invention provides a method and a system for screening diet-Parkinson's disease (PD) related genes. The method comprises the following steps: firstly, carrying out difference analysis on transcriptome data sets GSE8397 and GSE20295; a gene module is constructed through WGCNA; 8 types of diet phenotype target gene sets (high cholesterol / high glucose / high fat / high carbohydrate diet and egg / whole grain / mutton / fish intake), PD target gene sets (3907 targets) and DEGs are integrated, and candidate genes are screened in a cross mode; an analysis model is constructed by adopting a machine learning algorithm, a random forest algorithm is preferably selected, and 22 key genes are screened out by utilizing an SHAP value. A detection kit and an analysis system are developed based on the gene combination and are applied to PD mechanism research of A53T transgenic mouse models and human midbrain organs, and the molecular mechanism that diet intake affects PD pathology by adjusting dopaminergic neuron related genes is disclosed for the first time.